Medigene is a global leader in T Cell immunology.
Growing clinical pipeline in multiple indications and strong collaborations.
High-throughput platform for antigen and TCR discovery.
Listed on the Frankfurt Stock Exchange (Deutsche Börse) with a market cap of EUR 330 million.
Fundraising to expand the company's ongoing clinical program with its T-cell receptor modified T cells (TCR-T) and to progress its pipeline of potential TCR-T candidates for future clinical development.
Bryan, Garnier & Co acted as Lead Manager alongside Guggenheim Securities and Baader Bank.
EUR 32.3 million raised in an oversubscribed Accelerated Bookbuild targeting institutional investors in Europe and in the US.
Offering priced at EUR 14.5 per share representing a discount of 2.3% to the last market closing price.
Strong demand enabled QVT Financial LP, a major shareholder of Medigene, to sell c. 1.1 million shares in a secondary offering as part of a general restructuring across its funds.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Zurich and New York. The firm is a member of the London Stock Exchange and Euronext.
T: +49 89 242 262 66
T: +33 1 70 36 57 22
Managing Director – ECM
T: +33 1 56 68 75 17
Dr. Nicholas Hanser
Director – ECM
T: +49 89 242 262 70
Jean de Pracomtal
T: +33 1 56 68 75 38
T: +33 1 56 68 75 30
T: +33 1 56 68 75 76